Report Overview:

Lactulose Concentrate is a synthetic disaccharide composed of fructose and galactose, primarily used as a pharmaceutical and functional food ingredient. As a non-digestible sugar, it reaches the colon intact, where it is metabolized by gut microbiota to produce short-chain fatty acids and lower colonic pH, thereby stimulating bowel movements and aiding in the management of constipation, hepatic encephalopathy, and other gastrointestinal disorders. Beyond its therapeutic applications, lactulose concentrate is also employed in the food and beverage industry as a prebiotic to promote gut health. Its solubility, low glycemic index, and functional properties make it suitable for liquid formulations, syrups, and dietary supplements, serving both medical and consumer wellness markets.

The lactulose concentrate market is undergoing significant expansion and transformation, driven by increasing clinical recognition, technological innovation, and evolving market dynamics. Growing research demonstrates lactulose’s broad potential in gut health, immune regulation, metabolic modulation, and chronic disease management, highlighting its rising importance in pharmaceuticals, functional foods, and animal nutrition. In China, surging demand has prompted manufacturers such as Jiangxi Dankang, Hubei Guangchen, Baolingbao, and Hunan Baolishi to expand capacity, intensifying competition and reshaping market structure. Meanwhile, biological production methods, particularly enzymatic conversion using cellobiose 2-epimerase (CE) and high-cell-density fermentation, are gaining attention for higher product purity, environmental sustainability, and operational efficiency, despite technical limitations. Digital transformation and AI integration are further influencing the market, with short-video platforms enhancing brand IP and AI tools optimizing production efficiency and supporting sustainable practices.

By 2024, the global lactulose concentrate market reached USD 158.34 million and is projected to expand at a CAGR of 2.50% from 2025 to 2035, reaching USD 210.32 million. Market growth is primarily driven by demand in pharmaceuticals, functional foods, and infant nutrition. Rising global health awareness and increasing chronic disease prevalence, particularly in Asia-Pacific, have strengthened lactulose’s position as a key therapeutic for constipation, hepatic encephalopathy, and gut microbiota disorders. Population aging provides a stable, long-term demand foundation, as elderly consumers increasingly seek products that support gastrointestinal health. Rising attention to maternal and infant nutrition, the growth of prebiotics and functional foods, and improved healthcare infrastructure in emerging markets such as China and India further expand market potential.

Nevertheless, the market faces interconnected challenges. Demand remains sensitive to economic fluctuations; while medical demand for constipation and hepatic encephalopathy is stable, the functional food and consumer wellness segments are vulnerable to economic slowdowns, especially in emerging markets where reduced purchasing power increases price sensitivity. Intensifying global competition among multinational and local players elevates price pressures and necessitates continuous innovation, efficiency improvements, and strict quality control.

Segment-wise, chemical synthesis currently dominates the market, accounting for 84.37% of revenue in 2024, whereas enzymatic production, though smaller at 15.63%, is expected to grow rapidly with a CAGR of 8.59% from 2025 to 2033, reflecting a strong market shift toward biologically driven processes due to higher product purity, milder reaction conditions, and alignment with sustainability trends. By application, the pharmaceutical sector leads with a 76.01% market share in 2024, reflecting lactulose’s primary use in managing constipation and hepatic encephalopathy. The food industry is also growing steadily, with a CAGR of 3.07%, driven by lactulose’s use as a prebiotic and functional ingredient in processed foods and weight management products.

Geographically, the Asia-Pacific region dominates the market, capturing 48.00% of revenue in 2024, fueled by a large population, growing health awareness, and increasing applications across pharmaceuticals, functional foods, and infant nutrition. It is also projected to maintain the fastest growth with a CAGR of 3.09% from 2025 to 2033, underscoring its role as the primary driver of market expansion. North America and Europe hold significant shares of 24.92% and 19.23%, respectively, supported by high prevalence of chronic constipation, though their growth rates are more moderate at 1.53% and 1.77%.

Lactulose Concentrate Industry Chain Analysis

Key Development Trends

Research Results Drive Market Diversification        

Lactulose, a non-absorbable disaccharide, has been extensively explored in numerous clinical and experimental studies in recent years, demonstrating its potential in gut health, immune regulation, metabolic modulation, and the treatment of various diseases. Initially synthesized by Montgomery and Hudson in 1929, lactulose’s prebiotic properties were first discovered by Petuely and Mayerhofer in 1957. Since then, it has been widely used in treating conditions such as constipation, hepatic encephalopathy (HE), and gut dysbiosis. Further research, including work by Panesar and Kumari (2011), confirmed that lactulose promotes the growth of beneficial bacteria such as bifidobacteria, thereby regulating gut microbiota structure and function, making it an effective support agent for intestinal health.

Clinically, lactulose’s role in treating constipation and hepatic encephalopathy has gained broad recognition. For instance, Balzano (2023) reviewed lactulose’s clinical effectiveness in hepatic encephalopathy treatment, noting that lactulose reduces intestinal ammonia production, alleviates symptoms, and significantly lowers mortality rates. Additionally, a randomized controlled trial by Wang et al. (2023) demonstrated lactulose’s ability to improve gut function and promote short-chain fatty acid production in patients with acute pancreatitis and intestinal dysfunction, further supporting its potential in treating various diseases.

Lactulose’s benefits extend beyond gut health into immune function and the management of inflammatory bowel diseases (IBD). Karakan et al. (2021) showed that lactulose inhibits the growth of pathogenic bacteria, maintains gut microecology, and reduces the incidence of urinary tract and respiratory infections, enhancing overall immunity. Furthermore, lactulose has proven effective in reducing intestinal inflammation and promoting mineral absorption, including calcium, magnesium, zinc, and iron, through its short-chain fatty acid (SCFA) effects on intestinal acidification.

In animal nutrition, Elkomy et al. (2023) found that lactulose significantly improved egg production, egg quality, and overall performance in laying hens, while also enhancing gut function, increasing villus length, and promoting digestive enzyme activity. This study offers new insights into lactulose’s application in poultry farming, especially as an antibiotic-free feeding alternative.

As more research findings are published, lactulose’s broad application potential is increasingly recognized. Whether in gut health, immune function, metabolic disease management, or the food and animal nutrition sectors, lactulose’s prebiotic role is gaining greater acknowledgment among researchers.

Expansion of Lactulose Concentrate Production Capacity in China        

As demand for lactulose increases in China, several companies are actively expanding their production capacities. In recent years, particularly in the pharmaceutical and health supplement sectors, demand for lactulose has steadily risen, prompting companies to invest in expanding production capabilities. Specifically, companies such as Jiangxi Dankang Pharmaceutical, Hubei Guangchen Pharmaceutical, Baolingbao, and Hunan Baolishi have announced plans for large-scale lactulose production expansions.

For example, Jiangxi Dankang Pharmaceutical is undertaking a technological transformation of its lactulose concentrate production line, with a planned investment of 30 million RMB. This project will eliminate outdated equipment and implement digital transformation, boosting annual production capacity to 6,000 tons. Hubei Guangchen Pharmaceutical is investing 25 million RMB to establish a new lactulose production line at its existing facility, aiming for an annual production capacity of 2,000 tons upon completion. Hunan Baolishi plans to invest 62 million RMB to expand multiple production lines, including lactulose, with an annual output of 500 tons. Baolingbao is also advancing a strategic partnership with Beijing Fengli Pharmaceutical, working on the approval process for lactulose concentrate. This collaboration is expected to strengthen Baolingbao's competitive position in the domestic market. Additionally, Hebei Jiheng Pharmaceutical and other companies have announced similar capacity expansion plans. With more companies entering the market, China’s lactulose concentrate market will experience intense competition and a market reshuffling period in the coming years.

Biological Production Method Shows Growing Potential        

Lactulose's traditional production methods rely heavily on chemical processes. While these methods meet basic market demands, they face several challenges, including the production of byproducts, high costs, environmental pollution, and difficulties in controlling product purity, especially in pharmaceutical-grade products. These limitations have hindered lactulose’s broader application in various sectors. To address these issues, biological production methods for lactulose have emerged as a promising alternative. These methods, especially in terms of environmental friendliness, efficiency, and cost advantages, represent a sustainable solution for production.

The key enzyme in the biological production of lactulose is cellobiose 2-epimerase (CE). CE can efficiently catalyze the conversion of lactose into lactulose, offering fewer byproducts and higher conversion efficiency compared to traditional chemical methods. However, the current CE enzymes still face technical challenges, such as insufficient enzyme activity and poor stability, which limit their application in industrial-scale production. These issues need to be addressed through technological breakthroughs to support large-scale industrial production.

The industrial potential of CE is being continuously explored. In traditional biological production, lactose serves as the substrate. However, earlier β-galactosidase catalytic methods faced low conversion rates and required the addition of D-fructose as a secondary substrate, making the process complex and complicating product separation. The application of CE greatly simplifies this process, directly converting lactose into lactulose without the need for a second substrate, and offering higher conversion rates. With the advancement of biotechnology, particularly with AI-supported synthetic biology technologies, companies like Xinbeilai have developed next-generation CE variants, such as CE S+.

Additionally, high cell-density fermentation (HCDC) technology is providing technical support for CE enzyme industrialization. By increasing the microbial host’s cell density, more recombinant enzymes can be produced, reducing production costs and improving efficiency. Although research on CE enzymes in this area is still incomplete, further development in fermentation process control is expected to enhance the efficiency and economic viability of biological lactulose production.

Driving Factors

Rising Health Awareness and Increasing Chronic Disease Incidence        

The global rise in health awareness and the increasing prevalence of chronic diseases, especially in the Asia-Pacific region, are becoming key factors driving the demand for lactulose. The high incidence of chronic conditions such as diabetes, liver diseases, and constipation has led to increased demand for lactulose as a therapeutic agent and a key ingredient in health supplements.

Population aging, particularly the severe aging trends in East Asia, represents the most stable and enduring driver for the lactulose concentrate market. According to United Nations projections, by the late 2070s, the global population aged 65 and older is expected to reach 2.2 billion, surpassing the number of children under 18. By the mid-2030s, the population aged 80 and above will reach 265 million, exceeding the number of infants. The elderly population tends to suffer from poor gastrointestinal motility, gut microbiome imbalances, and higher rates of constipation, which leads to a consistent demand for products that improve gut function. Lactulose, as a first-line treatment for chronic constipation, is directly benefiting from the aging global population, which drives the demand for corresponding formulations and, subsequently, the consumption of lactulose concentrate.

The high prevalence of liver diseases, particularly the treatment needs for severe complications like hepatic encephalopathy, also provides a solid market foundation for lactulose. According to a 2022 study by the International Agency for Research on Cancer (IARC), the global number of liver cancer diagnoses and related deaths is expected to increase by more than 55% by 2040. Clinical data shows that 30-40% of liver cancer patients develop significant hepatic encephalopathy, while up to 70% of liver tumor patients experience varying degrees of hepatic encephalopathy symptoms. This trend has driven the continuous expansion of the lactulose formulation market, with lactulose remaining one of the primary drugs for treating hepatic encephalopathy.

Upgrading Maternal and Infant Nutrition        

The significant increase in demand for functional additives in infant formula is one of the key drivers for the expansion of the lactulose concentrate market. As nutritional standards for infants continue to improve, such as the implementation of China’s new national standards for infant formula, which stipulates that lactose must constitute at least 90% of carbohydrates in infant formula for babies aged 6-12 months, the demand for lactose and its derivatives has been strongly encouraged by policy.

In this context, lactulose, as a high-quality prebiotic, has seen its proportion in infant formula steadily increase. Lactulose effectively promotes the proliferation of beneficial gut bacteria, improving the intestinal health of infants, and has thus become an important functional additive in infant formula. In addition to infant foods, products specifically designed for children's nutrition have also shown good market prospects due to the growing demand for child nutrition.

The Rise of Prebiotics and Functional Foods        

Lactulose, as a key prebiotic, is no longer confined to the pharmaceutical industry but is gradually expanding into the functional food sector. With increasing consumer awareness of gut health, the demand for prebiotics is rapidly growing. Lactulose’s ability to stimulate the growth of beneficial gut bacteria, such as bifidobacteria, has made it an essential ingredient in prebiotic foods and dietary supplements. Currently, the application of lactulose in the prebiotic sector is not limited to treating constipation but also includes the prevention and improvement of various gut health issues, further driving its use in health supplements and functional foods.

In the food industry, the range of applications for lactulose is expanding quickly. With the "sugar reduction, not sweetness reduction" trend, lactulose is being widely used in products like candies and baked goods to meet the market's strong demand for low-sugar foods. Especially in new food product development, lactulose is regarded as an ideal alternative sweetener. Its dual role as a sugar substitute and a promoter of gut health has accelerated its adoption in candies, beverages, and baked goods.

This market trend further enhances lactulose’s functional ingredient properties. In the past, lactulose mainly relied on demand from the pharmaceutical industry, but with changing health consumption concepts, lactulose is transitioning from a traditional therapeutic drug to a functional ingredient with a broader market outlook.

.

Global Lactulose Concentrate Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Abbott

Fresenius Kabi Austria GmbH

Morinaga

Illovo Sugar

Lactitol India Private Limited (LIPL)

Merro pharmaceutical

Lactose (India) Limited

Solactis

Hubei Guangchen Pharmaceutical

Biofac AS

Jiangsu Hanstone Pharmaceutical

Dandong Kangfu

Sanes Pharmaceuticals

Syngars Technology Co Ltd

Others

Market Segmentation (by Type)

Chemical Synthesis

Enzymatic Method

Market Segmentation (by Application)

Pharmaceuticals

Food Industry

Others

Geographic Segmentation

North America

Europe

Asia-Pacific

South America

Middle East and Africa

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study

• Neutral perspective on the market performance

• Recent industry trends and developments

• Competitive landscape & strategies of key players

• Potential & niche segments and regions exhibiting promising growth covered

• Historical, current, and projected market size, in terms of value

• In-depth analysis of the Lactulose Concentrate Market

• Overview of the regional outlook of the Lactulose Concentrate Market:

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

• This enables you to anticipate market changes to remain ahead of your competitors

• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

• Provision of market value (USD Billion) data for each segment and sub-segment

• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

• Provides insight into the market through Value Chain

• Market dynamics scenario, along with growth opportunities of the market in the years to come

• 6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Lactulose Concentrate Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 details the production of products in major countries/regions and provides the production of major countries/regions.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 13 is the main points and conclusions of the report.